FF
LCTX icon

Farrow Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

Farrow Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9K Sell
10,646
-854
-7% -$1.18K 0.01% 55
2026
Q1 		$18.2K Hold
11,500
– – 0.01% 53
2025
Q4 		$19.2K Hold
11,500
– – 0.01% 53
2025
Q3 		$19.4K Hold
11,500
– – 0.01% 53
2025
Q2 		$10.4K Hold
11,500
– – 0.01% 51
2025
Q1 		$5.19K Hold
11,500
– – ﹤0.01% 50
2024
Q4 		$5.7K Hold
11,500
– – ﹤0.01% 50
2024
Q3 		$10.4K Hold
11,500
– – 0.01% 52
2024
Q2 		$11.5K Hold
11,500
– – 0.01% 50
2024
Q1 		$17K Sell
11,500
-5,500
-32% -$6.24K 0.01% 53
2023
Q4 		$18.5K Buy
+17,000
New +$18.6K 0.01% 51

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Farrow Financial's LCTX Position: Q2 2026 in Review

Farrow Financial reduced its Lineage Cell Therapeutics (LCTX) stake by 7.4% in Q2 2026, selling an estimated $1.18K and leaving 10,646 shares worth $13.9K. The position accounts for 0.01% of the portfolio, ranked #55.

Farrow Financial first reported a position in LCTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $19.4K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Farrow Financial held 10,646 shares of Lineage Cell Therapeutics worth $13.9K as of Q2 2026.
  • Farrow Financial sold 854 Lineage Cell Therapeutics shares in Q2 2026, an estimated $1.18K.
  • Lineage Cell Therapeutics made up 0.01% of Farrow Financial's portfolio in Q2 2026, its #55 holding.
  • Farrow Financial first reported a position in Lineage Cell Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Farrow Financial's Lineage Cell Therapeutics position peaked at $19.4K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Farrow Financial's 13F filing for Q2 2026, filed 4 Aug 2026.